The U.S. Drug Enforcement Administration has classified Orzeyful as a Schedule IV controlled substance, removing the final regulatory hurdle for Takeda to make the product available in the United States, investigators reported. The company described the pill as the first treatment to target the underlying cause of narcolepsy. The DEA’s Schedule IV designation signals a low potential for abuse and dependence relative to higher schedules, data indicated.
Takeda has set the U.S. list price at $16,500 per 60-tablet bottle across all strengths, the source reported. The article also stated that about 120,000 people in the U.S. have narcolepsy. The reporting cited Reuters for the launch and scheduling details. The source did not provide clinical trial efficacy or safety results, dosing regimens, or the timing of market rollout beyond the regulatory clearing action described.
The regulatory note is narrow but material: the DEA action addressed controlled-substance status, not questions about clinical benefit, comparative effectiveness, or payer coverage. The study team did not provide further information on manufacturer patient-assistance programs, prior-authorization expectations, or anticipated real-world uptake as part of this report.
Pfizer will no longer sell Premarin in Canada, the report stated, after conducting an internal review. Premarin had been available in Canada as a vaginal cream plus three tablet strengths for oral use. The company confirmed that Premarin vaginal cream has been in shortage in Canada since June and that no further batches will be supplied, the source noted.
Demand for hormone replacement therapy has been rising, particularly in the United States, the article reported; it attributed that rise to the U.S. Food and Drug Administration’s removal of long-standing safety warnings roughly a year earlier. The source also indicated that some other hormone therapy products used to treat menopause symptoms are facing supply constraints in Canada. The reporting agency cited for this item was Reuters.
The piece did not elaborate on Pfizer’s internal-review findings, manufacturing or supply-chain causes for the Canadian shortage, inventory forecasts, or explicit plans for alternative product distribution. The article likewise did not provide information on Canadian regulatory requirements that might have influenced the decision.
This Pharmalittle roundup included items drawn from Reuters reporting and was marked as exclusive material for STAT+ subscribers beyond the free highlights included here. The article identified Ed Silverman as the Pharmalot columnist and senior writer but the free excerpt on these specific items relied on Reuters as the underlying news source, the source reported.
Readers should note what the source did and did not report. It provided the DEA scheduling decision, the manufacturer’s list price for Orzeyful, an estimate of U.S. disease prevalence, and Pfizer’s decision to cease supplying Premarin in Canada with mention of shortages. The report did not provide trial-level data for Orzeyful, nor did it report specific manufacturing or regulatory documents underlying Pfizer’s Canada decision. Financial terms beyond list price, payer coverage policies, and patient-access mechanisms were not discussed in the excerpt.
Limitations and unanswered questions
The source did not include randomized trial outcomes, adverse-event summaries, or detailed regulatory review memoranda for Orzeyful. It also did not report Pfizer’s internal-review findings or timelines for restoring supply of other hormone therapies in Canada. Specifics on dosing, comparative effectiveness, or payer negotiations were absent from the article.
Next steps documented by the source
The only concrete next step described was the market availability of Orzeyful in the U.S. following the DEA’s scheduling action and Pfizer’s cessation of Premarin shipments to Canada. The report did not list additional regulatory milestones, clinical-readout dates, or manufacturer remediation plans, and these remain open questions for clinicians and payers seeking more detailed information.